{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:38:55Z","timestamp":1786984735964,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["archives-rrct.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Rehabilitation Research and Clinical Translation"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.arrct.2026.100590","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:08:10Z","timestamp":1769875690000},"page":"100590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring Treatment Expectations and Clinical Meaningfulness in Spinal Muscular Atrophy Using the Goal Attainment Scale"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6076-8869","authenticated-orcid":false,"given":"Jacopo","family":"Casiraghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Coratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Salmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Franchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cerri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Albamonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Ada","family":"Sansone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arrct.2026.100590_bib0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.arrct.2026.100590_bib0002","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.arrct.2026.100590_bib0003","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.arrct.2026.100590_bib0004","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.arrct.2026.100590_bib0005","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.arrct.2026.100590_bib0006","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40120-024-00653-2","article-title":"Effectiveness of nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and meta-analysis","volume":"13","author":"Hagenacker","year":"2024","journal-title":"Neurol Ther"},{"key":"10.1016\/j.arrct.2026.100590_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12mo) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.arrct.2026.100590_bib0008","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1474-4422(20)30068-5","article-title":"Nusinersen in adults with spinal muscular atrophy: new challenges","volume":"19","author":"Mercuri","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.arrct.2026.100590_bib0009","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3233\/JND-240003","article-title":"Patient-reported outcome measures in neuromuscular diseases: a scoping review","volume":"11","author":"Voet","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.arrct.2026.100590_bib0010","doi-asserted-by":"crossref","first-page":"e1206","DOI":"10.1212\/WNL.0000000000006241","article-title":"Patient Reported impact of symptoms in spinal muscular atrophy (PRISM-SMA)","volume":"91","author":"Mongiovi","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.arrct.2026.100590_bib0011","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.nmd.2021.02.006","article-title":"The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure","volume":"31","author":"Sansone","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.arrct.2026.100590_bib0012","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF01530764","article-title":"Goal attainment scaling: a general method for evaluating comprehensive community mental health programs","volume":"4","author":"Kiresuk","year":"1968","journal-title":"Community Ment Health J"},{"key":"10.1016\/j.arrct.2026.100590_bib0013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamacardio.2015.0248","article-title":"Moving from disease-centered to patient goals-directed care for patients with multiple chronic conditions: patient value-based care","volume":"1","author":"Tinetti","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.arrct.2026.100590_bib0014","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/0269215508101742","article-title":"Goal attainment scaling (GAS) in rehabilitation: a practical guide","volume":"23","author":"Turner-Stokes","year":"2009","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.arrct.2026.100590_bib0015","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2340\/16501977-0383","article-title":"Goal attainment scaling: does it provide added value as a person-centred measure for evaluation of outcome in neurorehabilitation following acquired brain injury?","volume":"41","author":"Turner-Stokes","year":"2009","journal-title":"J Rehabil Med"},{"key":"10.1016\/j.arrct.2026.100590_bib0016","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/0269215508101741","article-title":"Writing SMART rehabilitation goals and achieving goal attainment scaling: a practical guide","volume":"23","author":"Bovend\u2019Eerdt","year":"2009","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.arrct.2026.100590_bib0017","doi-asserted-by":"crossref","first-page":"M641","DOI":"10.1093\/gerona\/54.12.M641","article-title":"An individualized approach to outcome measurement in geriatric rehabilitation","volume":"54","author":"Stolee","year":"1999","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.arrct.2026.100590_bib0018","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0895-4356(03)00132-X","article-title":"Responsiveness of goal attainment scaling in a randomized controlled trial of comprehensive geriatric assessment","volume":"56","author":"Rockwood","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.arrct.2026.100590_bib0019","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0269215506070793","article-title":"Goal setting as an outcome measure: a systematic review","volume":"20","author":"Hurn","year":"2006","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.arrct.2026.100590_bib0020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0895-4356(97)00014-0","article-title":"Use of goal attainment scaling in measuring clinically important change in cognitive rehabilitation patients","volume":"50","author":"Rockwood","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.arrct.2026.100590_bib0021","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mus.27804","article-title":"Risdiplam in non-sitter patients aged 16\u2009years and older with 5q spinal muscular atrophy","volume":"67","author":"\u00d1ungo Garz\u00f3n","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arrct.2026.100590_bib0022","article-title":"Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: an international study","volume":"31","author":"Coratti","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.arrct.2026.100590_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.arrct.2026.100590_bib0024","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/mus.25120","article-title":"Six-minute walk test is reliable and valid in spinal muscular atrophy","volume":"54","author":"Dunaway Young","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arrct.2026.100590_bib0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.arrct.2026.100590_bib0026","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mus.26419","article-title":"Revised upper limb module for spinal muscular atrophy: 12\u2009month changes","volume":"59","author":"Pera","year":"2019","journal-title":"Muscle Nerve"},{"issue":"3-a Suppl","key":"10.1016\/j.arrct.2026.100590_bib0027","first-page":"S55","article-title":"Minimal clinically important differences in motor function in patients with infantile-onset spinal muscular atrophy: results from the Phase 3 ENDEAR trial","volume":"25","author":"Stull","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.arrct.2026.100590_bib0028","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3","volume":"91","author":"Maggi","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.arrct.2026.100590_bib0029","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/09638280701618828","article-title":"Goal attainment scaling: current methodological challenges","volume":"29","author":"Tennant","year":"2007","journal-title":"Disabil Rehabil"}],"container-title":["Archives of Rehabilitation Research and Clinical Translation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590109526000078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590109526000078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:14:18Z","timestamp":1781284458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590109526000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2590109526000078"],"URL":"https:\/\/doi.org\/10.1016\/j.arrct.2026.100590","relation":{},"ISSN":["2590-1095"],"issn-type":[{"value":"2590-1095","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring Treatment Expectations and Clinical Meaningfulness in Spinal Muscular Atrophy Using the Goal Attainment Scale","name":"articletitle","label":"Article Title"},{"value":"Archives of Rehabilitation Research and Clinical Translation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arrct.2026.100590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Congress of Rehabilitation Medicine.","name":"copyright","label":"Copyright"}],"article-number":"100590"}}